NCT06517420Completed
Effect of Kefir on Symptom Management and Quality of Life in Oncology
The Effect of Kefir on Symptom Management and Quality of Life in Oncology Patients Treated With Chemotherapy
Source: ClinicalTrials.gov · Last updated 24 Jul 2024
Brief summary (registry, in English)
This study was planned as a randomized controlled prospective experimental study to determine the effect of kefir on symptom management and quality of life in oncology patients receiving chemotherapy. The population of the study consisted of 600 cancer patients who received chemotherapy in the outpatient chemotherapy unit of a university hospital between June 1, 2023 and February 1, 2024. G\*Power 3.1 package program was used to determine the number of samples. The sample size to ensure the power of the test (1-β = 0.80) was determined as a minimum of 26 people for each group. Considering the possibility of losses, 106 patients were included in the study. Data from 22 patients who were followed up during the preparation phase of the study were not included in the study. Simple random sampling method was used to avoid bias in providing patients to be included in the study before the data collection phase. With the computer-based randomization method, patients were numbered in the order of arrival and divided into experimental and control. The sample of the study was determined as 84, 42 in the experimental group and 42 in the control group. In collecting data, "Individual Information Form, Nightingale Symptom Assessment Scale (NSD-S), FACT-G Quality of Life Scale, WHO Mucositis Evaluation Form, Rhodes Nausea Vomiting Gagging Index, ASCO Diarrhea Assessment Scale and Constipation Assessment Scale" were used. CAS)" was used.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 84 (actual)
- First submitted
- 18 Jul 2024
- Start date
- 1 Jun 2023
- Primary completion date
- 21 Aug 2023
- Lead sponsor
- Izmir Bakircay University
- Diseases
- Colorectal cancer
- NCT number
- NCT06517420
What you commit to
- Study type: Interventional
- Participants enrolled: 84
- From 1 Jun 2023 to the primary completion date, 21 Aug 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Allergy to milk and dairy products,
- Hearing and visual impairment,
Other
- Having lactose intolerance,
- Not volunteering to participate in the study,
- Having mental disability or perception problem
Who the study is looking for
- Being literate
- A diagnosis of breast and colorectal cancer
- Aged 18 or over
- The ability to communicate effectively and without language difficulties
- No diagnosis of mental or psychiatric illness
- No hearing or visual impairment
- No use of kefir, milk or dairy products prior to and/or during the treatment period
- The capacity to use a telephone for counselling
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Health Sciences University Izmir Tepecik Training and Research Hospital, Bornova Oncology Hospital, Additional Service Building Coordinator of this site? Confirm its status | Izmir | Turkey (Türkiye) | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.